Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Davies Scott M reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. Chief Legal Officer Scott M. Davies reported equity awards in the form of restricted stock units and performance stock units. He received 5,849 shares of common stock as restricted stock units that vest in four equal annual installments on February 15 of 2027, 2028, 2029, and 2030, subject to continued service.
He was also granted 6,824 performance stock units tied to three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, vesting on December 31, 2028, and 6,824 performance stock units tied to relative total shareholder return for the fiscal year ending December 31, 2028. For each performance award, the actual shares delivered can range from 0% to 250% of the target amount based on performance against predefined objectives and continued service.
ILLUMINA, INC. reported that SVP and Chief Financial Officer Ankur Dhingra acquired equity awards on March 5, 2026. He received 9,358 shares of common stock as restricted stock units, which vest 25% each on February 15 of 2027, 2028, 2029, and 2030, subject to continued service.
He was also granted 10,918 performance stock units tied to three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, and 10,918 performance stock units tied to relative total shareholder return for the fiscal year ending December 31, 2028. Each performance unit can settle into between 0% and 250% of the stated amount based on predefined objectives and continued service, and he held 34,264 shares of common stock directly after these grants.
Illumina, Inc. reported new equity awards for VP and Chief Accounting Officer Scott D. Ericksen. On March 5, 2026, he acquired grants of performance share units and restricted stock units, all recorded as awards rather than open-market purchases.
The filing shows two grants of 1,609 performance share units each, with the ultimate shares to be issued ranging from 0% to 250% of these amounts based on Illumina’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028 and on relative total shareholder return for the fiscal year ending December 31, 2028.
He also received 3,217 shares of common stock in the form of restricted stock units. These RSUs vest in four equal installments of 25% on February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, conditioned on his continued service.
Leckman Patricia reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. executive Patricia Leckman received new equity awards in the form of restricted stock units and performance shares. On March 5, 2026, she was granted 6,317 shares of common stock as restricted stock units that vest in four equal 25% installments each February 15 from 2027 through 2030, subject to continued service.
She was also granted two separate awards of 7,369 performance stock units each. One is tied to Illumina’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, vesting on December 31, 2028. The other is tied to the company’s relative total shareholder return for the fiscal year ending December 31, 2028. For each performance award, the actual shares ultimately issued can range from 0% to 250% of the stated amount, based on the company’s performance against predefined objectives and her continued service.
Illumina, Inc. reported that Chief of Global Operations Kevin Carl Pegels acquired new equity awards on March 5, 2026. He received 6,317 shares of common stock as restricted stock units at a reference price of $128.24 per share, vesting 25% each on February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, contingent on continued service.
He was also granted two tranches of performance stock units, each for 7,369 performance shares. One tranche vests on December 31, 2028 based on three-year average consolidated non-GAAP EPS growth for fiscal years 2026–2028, and the other on relative total shareholder return for the fiscal year ending December 31, 2028. In both cases, payout can range from 0% to 250% of the target amount, depending on performance and continued service. Following the common stock grant, he directly owned 29,038 shares of Illumina common stock.
ILLUMINA, INC. Chief Executive Officer Jacob Thaysen reported equity awards on common stock and performance shares. He was granted 25,734 shares of common stock on an award coded as an acquisition at a reported price of $128.24 per share, increasing his directly held common stock to 109,073 shares.
He also received two awards of performance shares, each covering 30,022 performance stock units at a reported price of $128.24 per unit. One restricted stock unit grant vests 25% on each of February 15, 2027, 2028, 2029, and 2030, subject to continued service. The performance stock units vest based on Illumina’s three‑year average non‑GAAP EPS growth for fiscal years 2026‑2028 and on relative total shareholder return for the fiscal year ending December 31, 2028, with payout ranging from 0% to 250% of the granted amount, contingent on predefined objectives and continued service.
Wedel Christensen Jakob reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. senior vice president Jakob Wedel Christensen reported awards of restricted stock units and performance stock units as part of his compensation. He received 5,615 shares of common stock in the form of restricted stock units that vest in four equal annual installments from February 15, 2027 through February 15, 2030, subject to continued service. He also received performance stock units that each represent a contingent right to one share of common stock, with payout ranging from 0% to 250% of the target amount based on non-GAAP earnings per share growth for fiscal years 2026–2028 and relative total shareholder return for the fiscal year ending December 31, 2028.
ILLUMINA, INC. Chief Legal Officer Scott M. Davies reported an open-market sale of common stock. On February 20, 2026, he sold 1,336 shares of Illumina common stock at an average price of $116.18 per share. After this transaction, he directly owned 16,334 shares of common stock.
Illumina affiliate Scott Davies reported an insider sale: 323 common shares were sold on 12/12/2025 for $43,957.07, with Morgan Stanley Smith Barney LLC listed as the broker. The filing also lists securities to be sold by the issuer: 410 Performance Stock Units dated 11/28/2025 and 926 Restricted Stock Units dated 02/15/2026.
ILLUMINA, INC. senior vice president and chief technology officer Steven Barnard reported a Form 4 transaction involving company common stock. On February 15, 2026, he disposed of 1,259 shares in a tax-withholding disposition to cover tax obligations, a non-open-market event. After this transaction, he directly owned 33,435 shares of Illumina common stock.